Skip to content

Debt-to-equity at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
0.7×0.0×
Merck & Co. logo
Merck & Co.MRK
1.1×+0.3×
UroGen Pharma logo
UroGen PharmaURGN
4.8×
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
0.0×
CG Oncology logo
CG OncologyCGON
0.0×
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
0.9×0.0×

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Current ratio7.1×-4.0×

Where this comes from

Calculated from Aura Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s debt-to-equity?
Aura Biosciences, Inc. (AURA) reported debt-to-equity of 0.2× in Q1 2026.
How has Aura Biosciences, Inc.'s debt-to-equity changed year-over-year?
Aura Biosciences, Inc.'s debt-to-equity increased by 9.9% year-over-year, from 0.1× to 0.2×.
What is the long-term trend for Aura Biosciences, Inc.'s debt-to-equity?
Over 4 years (2021 to 2025), Aura Biosciences, Inc.'s debt-to-equity has grown at a 111.0% compound annual growth rate (CAGR), from 0× to 0.1×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.